Skip to content

AFS Securities at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$894.72M+186%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$67.48M+194%
Nuvation Bio logo
Nuvation BioNUVB
$365.13M-21.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$121M+76.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.33B+63.3%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$630.67M-7.4%

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s AFS securities?
Nurix Therapeutics, Inc. (NRIX) reported AFS securities of $0 in Q4 2025.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.